Shares of Zymeworks Inc. (ZYME) are rising more than 10% Monday morning after reporting positive topline results from the Phase 2b study of zanidatamab in patients with biliary tract cancers.
Topline results from the Phase 2b HERIZON-BTC-01 study showed that 41.3% of enrolled patients with HER2-amplified and expressing disease achieved an objective response after treatment with zanidatamab.
Full results from the study are expected to be presented in 2023.
ZYME is at $7.17 currently. It has traded in the range of $4.11-$17.27 in the last 1 year.
Source: Read Full Article
Lates News:
-
Cryptos Rise As Powell Sounds Less Hawkish Than Feared
-
Institutional Investors and Other Large Traders See Bitcoin ($BTC) Reach $32,000 This Year
-
Despite Bitcoin’s 70% Rally, ‘Historic Undervaluation Remains’, Explains Crypto Analyst
-
Bitcoin Price Bounces Back To $26,000, Here's Why
-
This Bitcoiner Just Paid a Whopping $500,000 In Transaction Fees for A 0.074 BTC Transfer